{
    "organizations": [],
    "uuid": "37b5d5bef367ba9adae417e7706ea4cf5a438ac7",
    "author": "",
    "url": "https://www.reuters.com/article/brief-dermira-initiates-mid-stage-study/brief-dermira-initiates-mid-stage-study-testing-eczema-treatment-idUSFWN1PQ18J",
    "ord_in_thread": 0,
    "title": "BRIEF-Dermira Initiates Mid-Stage Study Testing Eczema Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 31, 2018 / 1:44 PM / Updated 9 minutes ago BRIEF-Dermira Initiates Mid-Stage Study Testing Eczema Treatment Reuters Staff \nJan 31 (Reuters) - Dermira Inc: \n* DERMIRA INITIATES PHASE 2B DOSE-RANGING STUDY EVALUATING LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS \n* DERMIRA INC - ‍TOPLINE RESULTS FROM PHASE 2B DOSE-RANGING STUDY​ EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-01-31T15:42:00.000+02:00",
    "crawled": "2018-01-31T15:59:40.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "initiate",
        "study",
        "testing",
        "eczema",
        "treatment",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "dermira",
        "inc",
        "dermira",
        "initiate",
        "phase",
        "2b",
        "study",
        "evaluating",
        "lebrikizumab",
        "patient",
        "atopic",
        "dermatitis",
        "dermira",
        "inc",
        "result",
        "phase",
        "2b",
        "expected",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}